Showing results (441-450 of 623) with videos related to
Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.Nature Medicine|February 9, 2026
Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedentsAbraham Shaked, Alex Sagar, Kim M Olthoff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2015
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Roy S Herbst, David R Gandara, Fred R Hirsch, et al.Biorxiv : the Preprint Server for Biology|May 11, 2021
Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.Frontiers in Immunology|March 21, 2022
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.Journal of the National Cancer Institute|June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trialsJeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.Journal of the National Cancer Institute|January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignKeith T Flaherty, Robert Gray, Alice Chen, et al.Pageof 63